Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination on August 11, 2025, between Helix Acquisition Corp. II ("Helix") and TheRas, Inc. (d/b/a BridgeBio Oncology Therapeutics, or "BBOT"). Helix domesticated as a Delaware corporation, merged with BBOT, and changed its name to BridgeBio Oncology Therapeutics, Inc. ("PubCo"). PubCo Common Stock began trading on the Nasdaq Global Market under the symbol "BBOT" on the Closing Date.
Key Financial Metrics and Capital Structure
- Total Proceeds: PubCo received gross proceeds of approximately $381.8 million prior to transaction expenses.
- Capital Sources: Proceeds comprised $120.9 million from Helix's trust account and $260.9 million from a PIPE Investment.
- Redemptions: 7,119,750 Helix Class A Shares were redeemed at approximately $10.7173 per share, totaling approximately $76.3 million.
- PIPE Investment: PIPE Investors purchased 24,343,711 shares at $10.7173 per share.
- Share Count: As of the Closing Date, 79,196,710 shares of PubCo Common Stock were issued and outstanding.
- Options: 4,078,552 options to purchase PubCo Common Stock were issued to BBOT stockholders.
- Historical Financials: The filing incorporates by reference BBOT's audited financial statements for years ended December 31, 2024 and 2023, and unaudited statements for the six months ended June 30, 2025. Specific revenue, profit, or cash flow figures for these periods are not detailed in the text of this 8-K.
Material Changes and Corporate Actions
- Corporate Status: Helix ceased to be a shell company and became a holding company with equity interests in BBOT as its sole asset.
- Share Conversion: BBOT stockholders received PubCo Common Stock at a consideration ratio of approximately 0.0889. BBOT options were converted to PubCo options with adjusted share counts and exercise prices.
- Accounting Firm Change: PubCo dismissed WithumSmith+Brown, PC and engaged Deloitte & Touche LLP as its independent registered public accounting firm.
- Management Appointments: Eli Wallace was appointed CEO; Uneek Mehra was appointed CFO; Pedro Beltran was appointed Chief Scientific Officer; and Yong Ben was appointed Chief Medical and Development Officer.
Guidance, Outlook, and Risks
Outlook and Clinical Pipeline: Management provided forward-looking statements regarding the potential of product candidates, specifically mentioning clinical trials for ONKORAS-101, BREAKER-101, and KONQUER-101, as well as the therapeutic potential of BBO-8520, BBO-10203, and BBO-11818. No specific financial guidance or revenue projections were provided in this filing.
Risks and Contingencies: Key risks include the uncertainty of clinical trial outcomes, regulatory approval timelines, the ability to commercialize products, and the impact of competition. The filing notes that actual results may differ materially from forward-looking statements due to various factors, including global economic conditions and intellectual property claims.
Lock-Up Agreements: Helix Insiders are subject to a one-year lock-up period. BBOT stockholders (Lock-Up Holders) are subject to a six-month lock-up if they are employees below the Vice President level, or a one-year lock-up otherwise.
Investor Verification Checklist
- Verify the final share count and ownership percentages of major holders (e.g., Cormorant Asset Management at 22.6% and BridgeBio Pharma LLC at 17.5%) in subsequent filings.
- Review the unaudited pro forma condensed combined financial information (Exhibit 99.2) for a detailed view of the combined entity's financial position.
- Monitor the progress and data readouts of the ONKORAS-101, BREAKER-101, and KONQUER-101 clinical trials as referenced in the forward-looking statements.
- Confirm the effectiveness of the Resale Registration Statement for the 61.1 million shares subject to registration rights.
- Check for any updates on the engagement of Deloitte & Touche LLP and the transition of audit responsibilities.